Search

Your search keyword '"Fragkou, Paraskevi C."' showing total 193 results
Start Over Author "Fragkou, Paraskevi C."
193 results on '"Fragkou, Paraskevi C."'

1. SARS-CoV-2 seroprevalence among children in Greece during Omicron variant period

Author

Dimopoulou, Dimitra, Sotiri, Despoina, Kousi, Dimitra, Loulou, Garyfallia, Raptaki, Kalliopi, Neofytou, Ariadni, Dasoula, Foteini, Tampouratzi, Maria, Koloi, Athina, Eleftheriou, Eirini, Vergadi, Eleni, Papadimitriou, Eleni, Zorbadaki, Irini, Mavridi, Artemis, Miliordos, Konstantinos, Steletou, Evangelia, Strempela, Maria, Fragkou, Paraskevi C., Spoulou, Vassiliki, Michos, Athanasios, Gkentzi, Despoina, Papaevangelou, Vassiliki, Ladomenou, Fani, Grivea, Ioanna, Syrogiannopoulos, George, Galanakis, Emmanouil, Zaoutis, Theoklis, Tryfinopoulou, Kyriaki, and Tsolia, Maria N.

Published
2024
Full Text
View/download PDF

6. Update in Viral Infections in the Intensive Care Unit.

Author

Fragkou, Paraskevi C, Moschopoulos, Charalampos D, Karofylakis, Emmanouil, Kelesidis, Theodoros, and Tsiodras, Sotirios

Subjects
critical care, critically ill, intensive care unit, neurologic syndrome, reactivation, respiratory tract infection, shock, viral infections
Abstract

The advent of highly sensitive molecular diagnostic techniques has improved our ability to detect viral pathogens leading to severe and often fatal infections that require admission to the Intensive Care Unit (ICU). Viral infections in the ICU have pleomorphic clinical presentations including pneumonia, acute respiratory distress syndrome, respiratory failure, central or peripheral nervous system manifestations, and viral-induced shock. Besides de novo infections, certain viruses fall into latency and can be reactivated in both immunosuppressed and immunocompetent critically ill patients. Depending on the viral strain, transmission occurs either directly through contact with infectious materials and large droplets, or indirectly through suspended air particles (airborne transmission of droplet nuclei). Many viruses can efficiently spread within hospital environment leading to in-hospital outbreaks, sometimes with high rates of mortality and morbidity, thus infection control measures are of paramount importance. Despite the advances in detecting viral pathogens, limited progress has been made in antiviral treatments, contributing to unexpectedly high rates of unfavorable outcomes. Herein, we review the most updated data on epidemiology, common clinical features, diagnosis, pathogenesis, treatment and prevention of severe community- and hospital-acquired viral infections in the ICU settings.

Published
2021

7. Update of European Society of Clinical Microbiology and Infectious Diseases coronavirus disease 2019 guidelines: diagnostic testing for severe acute respiratory syndrome coronavirus 2

Author

Fragkou, Paraskevi C., De Angelis, Giulia, Menchinelli, Giulia, Can, Fusun, Garcia, Federico, Morfin-Sherpa, Florence, Dimopoulou, Dimitra, Dimopoulou, Konstantina, Zelli, Silvia, de Salazar, Adolfo, Reiter, Rieke, Janocha, Hannah, Grossi, Adriano, Omony, Jimmy, and Skevaki, Chrysanthi

Published
2023
Full Text
View/download PDF

9. Performance of point-of care molecular and antigen-based tests for SARS-CoV-2: a living systematic review and meta-analysis

Author

Fragkou, Paraskevi C., Moschopoulos, Charalampos D., Dimopoulou, Dimitra, Ong, David S.Y., Dimopoulou, Konstantina, Nelson, Philipp P., Schweitzer, Valentijn A., Janocha, Hannah, Karofylakis, Emmanouil, Papathanasiou, Konstantinos A., Tsiordras, Sotirios, De Angelis, Giulia, Thölken, Clemens, Sanguinetti, Maurizio, Chung, Ho-Ryun, and Skevaki, Chrysanthi

Published
2023
Full Text
View/download PDF

13. Duration of Antimicrobial Treatment in Adult Patients with Pneumonia: A Narrative Review.

Author

Dimopoulou, Dimitra, Moschopoulos, Charalampos D., Dimopoulou, Konstantina, Dimopoulou, Anastasia, Berikopoulou, Maria M., Andrianakis, Ilias, Tsiodras, Sotirios, Kotanidou, Anastasia, and Fragkou, Paraskevi C.

Subjects
VENTILATOR-associated pneumonia, COMMUNITY-acquired pneumonia, GRAM-negative bacteria, ADULTS, TREATMENT duration
Abstract

Pneumonia remains a major global health concern, causing significant morbidity and mortality among adults. This narrative review assesses the optimal duration of antimicrobial treatment in adults with community-acquired pneumonia (CAP), hospital-acquired pneumonia (HAP), and ventilator-associated pneumonia (VAP). Current evidence about the impact of treatment duration on clinical outcomes demonstrates that shorter antibiotic courses are non-inferior, regarding safety and efficacy, compared to longer courses, particularly in patients with mild to moderate CAP, which is in line with the recommendations of international guidelines. Data are limited regarding the optimal antimicrobial duration in HAP patients, and it should be individually tailored to each patient, taking into account the causative pathogen and the clinical response. Shorter courses are found to be as effective as longer courses in the management of VAP, except for pneumonia caused by non-fermenting Gram-negative bacteria; however, duration should be balanced between the possibility of higher recurrence rates and the documented benefits with shorter courses. Additionally, the validation of reliable biomarkers or clinical predictors that identify patients who would benefit from shorter therapy is crucial. Insights from this review may lead to future research on personalized antimicrobial therapies in pneumonia, in order to improve patient outcomes. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

17. Risk of stroke in hospitalized SARS-CoV-2 infected patients: A multinational study

Author

Shahjouei, Shima, Naderi, Soheil, Li, Jiang, Khan, Ayesha, Chaudhary, Durgesh, Farahmand, Ghasem, Male, Shailesh, Griessenauer, Christoph, Sabra, Mirna, Mondello, Stefania, Cernigliaro, Achille, Khodadadi, Faezeh, Dev, Apoorva, Goyal, Nitin, Ranji-Burachaloo, Sakineh, Olulana, Oluwaseyi, Avula, Venkatesh, Ebrahimzadeh, Seyed Amir, Alizada, Orkhan, Hancı, Mehmet Murat, Ghorbani, Askar, Vaghefi far, Alaleh, Ranta, Annemarei, Punter, Martin, Ramezani, Mahtab, Ostadrahimi, Nima, Tsivgoulis, Georgios, Fragkou, Paraskevi C., Nowrouzi-Sohrabi, Peyman, Karofylakis, Emmanouil, Tsiodras, Sotirios, Neshin Aghayari Sheikh, Saeideh, Saberi, Alia, Niemelä, Mika, Rezai Jahromi, Behnam, Mowla, Ashkan, Mashayekhi, Mahsa, Bavarsad Shahripour, Reza, Sajedi, Seyed Aidin, Ghorbani, Mohammad, Kia, Arash, Rahimian, Nasrin, Abedi, Vida, and Zand, Ramin

Published
2020
Full Text
View/download PDF

24. Intensive Care Unit Mortality Trends during the First Two Years of the COVID-19 Pandemic in Greece: A Multi-Center Retrospective Study.

Author

Fragkou, Paraskevi C., Karagiannis, Sotirios P., Dimopoulou, Dimitra, Kefala, Sotiria, Fligou, Fotini, Gallos, Parisis, Jahaj, Edison, Bellou, Angeliki, Koukaki, Evangelia, Magira, Eleni, Orfanos, Philippos, Papathanakos, Georgios, Papathanasiou, Athanasios, Pediaditis, Emmanouil, Pontikis, Konstantinos, Rovina, Nikoletta, Vaporidi, Katerina, Xenikakis, Menelaos, Theodorakopoulou, Maria, and Kotanidou, Anastasia

Subjects
*COVID-19 pandemic, *INTENSIVE care units, *COVID-19, *TREATMENT delay (Medicine), *INTENSIVE care patients, *MORTALITY
Abstract

Data on COVID-19 mortality among patients in intensive care units (ICUs) from Eastern and/or Southern European countries, including Greece, are limited. The purpose of this study was to evaluate the ICU mortality trends among critically ill COVID-19 patients during the first two years of the pandemic in Greece and to further investigate if certain patients' clinical characteristics contributed to this outcome. We conducted a multi-center retrospective observational study among five large university hospitals in Greece, between February 2020 and January 2022. All adult critically ill patients with confirmed COVID-19 disease who required ICU admission for at least 24 h were eligible. In total, 1462 patients (66.35% males) were included in this study. The mean age of this cohort was 64.9 (±13.27) years old. The 28-day mortality rate was 35.99% (n = 528), while the overall in-hospital mortality was 50.96% (n = 745). Cox regression analysis demonstrated that older age (≥65 years old), a body mass index within the normal range, and a delay in ICU admission from symptom onset, as well as worse baseline clinical severity scores upon ICU admission, were associated with a greater risk of death. Mortality of critically ill COVID-19 patients was high during the first two years of the pandemic in Greece but comparable to other countries. Risk factors for death presented in this study are not different from those that have already been described for COVID-19 in other studies. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

26. Endothelial Glycocalyx Integrity in Treatment-Naïve People Living with HIV before and One Year after Antiretroviral Treatment Initiation

Author

Fragkou, Paraskevi C., primary, Ikonomidis, Ignatios, additional, Benas, Dimitrios, additional, Kavatha, Dimitra, additional, Moschopoulos, Charalampos D., additional, Protopapas, Konstantinos, additional, Kostelli, Gavriella, additional, Thymis, John, additional, Mpirmpa, Dionysia, additional, Galani, Irene, additional, Tsakona, Maria, additional, Oikonomopoulou, Chrysanthi, additional, Theocharous, George, additional, Gorgoulis, Vassilis G., additional, Gallos, Parisis, additional, Tsiodras, Sotirios, additional, Antoniadou, Anastasia, additional, Papadopoulos, Antonios, additional, and Triantafyllidi, Helen, additional

Published
2023
Full Text
View/download PDF

27. New Insights into the Fluid Management in Patients with Septic Shock

Author

Moschopoulos, Charalampos D., primary, Dimopoulou, Dimitra, additional, Dimopoulou, Anastasia, additional, Dimopoulou, Konstantina, additional, Protopapas, Konstantinos, additional, Zavras, Nikolaos, additional, Tsiodras, Sotirios, additional, Kotanidou, Anastasia, additional, and Fragkou, Paraskevi C., additional

Published
2023
Full Text
View/download PDF

28. Update of ESCMID COVID-19 guidelines: diagnostic testing for SARS-CoV-2

Author

Fragkou, Paraskevi C., primary, De Angelis, Giulia, additional, Menchinelli, Giulia, additional, Can, Fusun, additional, Garcia, Federico, additional, Morfin-Sherpa, Florence, additional, Dimopoulou, Dimitra, additional, Dimopoulou, Konstantina, additional, Zelli, Silvia, additional, de Salazar, Adolfo, additional, Reiter, Rieke, additional, Janocha, Hannah, additional, Grossi, Adriano, additional, Omony, Jimmy, additional, and Skevaki, Chrysanthi, additional

Published
2023
Full Text
View/download PDF

29. Autoantibodies are highly prevalent in non–SARS-CoV-2 respiratory infections and critical illness

Author

Feng, Allan, primary, Yang, Emily Y., additional, Moore, Andrew Reese, additional, Dhingra, Shaurya, additional, Chang, Sarah Esther, additional, Yin, Xihui, additional, Pi, Ruoxi, additional, Mack, Elisabeth K.M., additional, Völkel, Sara, additional, Geßner, Reinhard, additional, Gündisch, Margrit, additional, Neubauer, Andreas, additional, Renz, Harald, additional, Tsiodras, Sotirios, additional, Fragkou, Paraskevi C., additional, Asuni, Adijat A., additional, Levitt, Joseph E., additional, Wilson, Jennifer G., additional, Leong, Michelle, additional, Lumb, Jennifer H., additional, Mao, Rong, additional, Pinedo, Kassandra, additional, Roque, Jonasel, additional, Richards, Christopher M., additional, Stabile, Mikayla, additional, Swaminathan, Gayathri, additional, Salagianni, Maria L., additional, Triantafyllia, Vasiliki, additional, Bertrams, Wilhelm, additional, Blish, Catherine A., additional, Carette, Jan E., additional, Frankovich, Jennifer, additional, Meffre, Eric, additional, Nadeau, Kari Christine, additional, Singh, Upinder, additional, Wang, Taia T., additional, Luning Prak, Eline T., additional, Herold, Susanne, additional, Andreakos, Evangelos, additional, Schmeck, Bernd, additional, Skevaki, Chrysanthi, additional, Rogers, Angela J., additional, and Utz, Paul J., additional

Published
2023
Full Text
View/download PDF

30. Autoantibodies against type I IFNs in patients with critical influenza pneumonia

Author

Zhang, Qian, Pizzorno, Andrés, Miorin, Lisa, Bastard, Paul, Gervais, Adrian, Le Voyer, Tom, Bizien, Lucy, Manry, Jeremy, Rosain, Jérémie, Philippot, Quentin, Goavec, Kelian, Wroblewski, Isabelle, Husebye, Eystein, Fellay, Jacques, Pothier, Pierre, Morand, Patrice, Navarrete, Nicolás, Franco, José Luis, Uddin, Mohammed J., Carratalà, Jordi, Merino Díaz, Laura, Palomo, Virginia, Seppänen, Mikko R.J., Särekannu, Karita, Aiuti, Alessandro, Retamar Gentil, Pilar, Debette, Stéphanie, Belot, Alexandre, Abel, Laurent, Soler Palacín, Pere, Abad Arranz, Maria, Aguilar Guisado, Manuela, Meyts, Isabelle, Casanova, Jean-Laurent, Gonzalez Granado, Luis L., Butte, Manish J., Itan, Yuval, Escoresca Ortega, Ana, Morio, Tomohiro, Padey, Blandine, Niubó, Jordi, Gallardo Ríos, Rafaela, Lau, Yu-lung, Triantafyllia, Vasiliki, Briones, Marisa, Saker, Kahina, Richard, Pascale, Drolet, Beth A., Espinosa Padilla, Sara, Wauters, Joost, Peigue Lafeuille, Helene, Valiente, Adoración, El Baghdadi, Jamila, Tiberghien, Pierre, Balsera-manzanero, María, Zins, Marie, Hammarström, Lennart, Andreakos, Evangelos, Notarangelo, Luigi D., Prando, Carolina, Condino-neto, Antonio, Dominguez Pinilla, Nerea, Aydillo, Teresa, Okamoto, Keisuke, Soumaré, Aïcha, Karamitros, Timokratis, Medina, Rafael A., Kisand, Kai, Ramírez Duque, Nieves, Feys, Simon, Romero Oraa, Laura, Kuo, Chen-yen, Lei, Wei-te, Quintana Murci, Lluis, Milner, Joshua D., Ku, Cheng-lung, Van De Beek, Diederik, Hsieh, Elena W.Y., Tal, Galit, Fournet, Thomas, Cerba Healthcare Group, Patural, Hugues, Novelli, Giuseppe, Lyon Antigrippe Working Group, Arias, Andrés A., Rovina, Nikoletta, Rodríguez-gallego, Carlos, Puel, Anne, Jouanguy, Emmanuelle, Vinh, Donald C., Henny, Joseph, Mogensen, Trine H., Cobat, Aurélie, Casari, Giorgio, Ramaswamy, Sathishkumar, Abelenda Alonso, Gabriela, Morel, Pascal, Trouillet Assant, Sophie, Tzourio, Christophe, Gallian, Pierre, Reipi Inf Working Group, García Sastre, Adolfo, Constantinescu, Stefan N., Hamzeh Cognasse, Hind, Haerynck, Filomeen, Flores, Carlos, Bousfiha, Ahmed A., García Salum, Tamara, Shahrooei, Mohammed, Slaby, Ondrej, Fragkou, Paraskevi C., Argaud, Laurent, Shcherbina, Anna, Al-muhsen, Saleh, Biggs, Catherine M., Bogunovic, Dusan, Planas, Anna M., Heath, James R., Von Bernuth, Horst, Dufouil, Carole, Bolze, Alexandre, Boeuf, Benoit, Rodríguez Gallego, Carlos, Christodoulou, John, Bondarenko, Anastasiia, Martin, Fernando, Koltsida, Ourania, Sediva, Anna, Ruiz Hernandez, José Juan, Bonneaudeau, Brigitte, Cannet, Dorothée, Etablissement Français Du Sang Study Group, Froidure, Antoine, Laurent, Emilie, Galani, Ioanna Evdokia, Gregersen, Peter K., Lemonnier, Sylvie, Spaan, András N., Darmon, Michael, Grimbacher, Bodo, Del Mar Muñoz Garcia, Maria, Zawadzki, Pawel, Henrickson, Sarah E., O'farrelly, Cliona, Rosa Calatrava, Manuel, Lachaize, Morgane, Okada, Satoshi, Vanker, Martti, Bryceson, Yenan, Ling, Yun, Cooper, Megan A., Lucas, Carrie L., Maniatis, Tom, Romero Vázquez, Gloria María, Mansouri, Davood, Castagnoli, Riccardo, Maródi, László, Mironska, Kristina, Rapti, Vasiliki, Baris Feldman, Hagit, Pozzetto, Bruno, Renia, Laurent, Tancevski, Ivan, Imai, Kohsuke, Ozcelik, Tayfun, Pan-hammarström, Qiang, Al-mulla, Fahd, Pape, Jean W., Etzioni, Amos, Souweine, Bertrand, Perez De Diego, Rebeca, Sánchez Cordero, Maria Jose, Solé Violán, Jordi, Perlin, David S., Queromes, Gregory, Anderson, Mark S., Resnick, Igor, Pesole, Graziano, Su, Helen C., Vanderbeke, Lore, Hagin, David, Jeanne, Michel, Desai, Murkesh, Ferres, Marcela, Sánchez Céspedes, Javier, Perroquin, Magali, Ng, Lisa F.P., Abou Tayoun, Ahmad, Le Corre, Nicole, Snow, Andrew L., Temel, Şehime Gülsün, Tsiodras, Sotirios, Coeuret Pellicer, Mireille, Javouhey, Etienne, Turvey, Stuart E., Covid Human Genetic Effort, Rombauts, Alexander, Zatz, Mayana, Uddin, K.m. Furkan, Fievet, Nathalie, Jarvis, Erich D., Rodríguez De Castro, Felipe, Ferreres, José, Flaig, Amandine, Pujol, Aurora, Cognasse, Fabrice, Sancho Shimizu, Vanessa, Nadif, Rachel, Hanna, Suhair, Constances Cohort, Goldberg, Marcel, Brodin, Petter, Le Got, Stéphane, Ozguler, Anna, Quenot, Jean Pierre, Novelli, Antonio, Cordero, Elisa, Colomb, Benoit, Cupic, Anastasija, Mehlal Sedkaoui, Souad, Sallette, Jérôme, Hernu, Romain, Bustamante, Carlos D., Lina, Bruno, Halwani, Rabih, Casalegno, Jean Sebastien, Schwebel, Carole, Salamanca Rivera, Celia, 3C-Dijon Study, Tangye, Stuart G., Dalgard, Clifton L., Howard Hughes Medical Institute, Rockefeller University, St. Giles Foundation, National Institutes of Health (US), National Center for Advancing Translational Sciences (US), Fisher Center for Alzheimer's Research Foundation, Meyer Foundation, JPB Foundation, Agence Nationale de la Recherche (France), European Commission, Square Foundation, Ministre de l'Enseignement Supérieur, de la Recherche et de l'Innovation (France), Institut National de la Santé et de la Recherche Médicale (France), Université Paris Cité, Center for Research for Influenza Pathogenesis (US), National Institute of Allergy and Infectious Diseases (US), Center of Excellence for Influenza Research and Response (US) CEIRR, Agencia Nacional de Investigación y Desarrollo (Chile), Centre National de la Recherche Scientifique (France), Ministère des Solidarités et de la Santé (France), Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación (España), Fundación Mapfre, Sociedad Española de Neumología y Cirugía Torácica, Cabildo de Tenerife, Hellenic Foundation for Research and Innovation, Fondation pour la Recherche Médicale, Fondation Bettencourt Schueller, Ministerio de Ciencia, Innovación y Universidades (España), Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (España), Junta de Andalucía, Research Foundation - Flanders, Imagine - Institut des maladies génétiques (IHU) (Imagine - U1163), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Centre International de Recherche en Infectiologie (CIRI), École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Etablissement Français du Sang [La Plaine Saint-Denis] (EFS), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Laboratoire de Biotechnologie et Microbiologie Appliquée (LBMA), Université Bordeaux Segalen - Bordeaux 2-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Bordeaux population health (BPH), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre National de Référence des Virus des Infections Respiratoires (dont la Grippe) [Lyon] (CNR - laboratoire associé), Institut des Agents Infectieux [Lyon] (IAI), Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), 01057100, HORIZON-HLTH-2021-DISEASE-04, MESRI-COVID-19, ANR-10-LABX-62-IBEID, P18-RT-3320, CGIEU0000219140, RTC-2017-6471-1, REIPI RD16/0016/0009, National Institutes of Health, NIH: R01AI088364, R01AI163029, Howard Hughes Medical Institute, HHMI, National Institute of Allergy and Infectious Diseases, NIAID: 75N93021C00014, U19AI135972, U19AI142733, U19AI168631, Jeffrey Modell Foundation, JMF, Glenn Foundation for Medical Research, GFMR: ANRS-COV05, EA20170638020, EQU201903007798, Pfizer, Albert Ellis Institute, AEI, National Center for Advancing Translational Sciences, NCATS: UL1 TR001866, JPB Foundation, JPBF, Horizon 2020 Framework Programme, H2020: 824110, Fondation du Souffle, FdS, College of Natural Resources and Sciences, Humboldt State University, CNRS, Ministerio de Ciencia, Innovación y Universidades, MCIU, Instituto Tecnológico y de Energías Renovables, ITER, SCOR Corporate Foundation for Science, Agence Nationale de la Recherche, ANR: ANR-10-IAHU-01, Institut National de la Santé et de la Recherche Médicale, Inserm, Fondo Nacional de Desarrollo Científico y Tecnológico, FONDECYT: 1161971, 1212023, Association Nationale de la Recherche et de la Technologie, ANRT, Fonds Wetenschappelijk Onderzoek, FWO: G0B5120N, G0C8517N, G0E8420N, KU Leuven: C16/18/007, Instituto de Salud Carlos III, ISCIII: COV20_01333, COV20_01334, PI12/01565, European Regional Development Fund, ERDF: CB21/13/00006, University of the East, UE, Hellenic Foundation for Research and Innovation, ΕΛ.ΙΔ.Ε.Κ, Université de Paris, SINOVAC outside the submitted work. P. Retamar-Gentil reported personal fees from Merck outside the submitted work. I. Meyts reported grants from CSL-Behring outside the submitted work. E. Andreakos reported grants from Janssen Pharmaceuticals during the conduct of the study. J. Wauters reported grants and personal fees from Pfizer and Gilead outside the submitted work. L. Vanderbeke reported grants from Research Foundation Flanders and non-financial support from Pfizer outside the submitted work. S. Feys reported grants from Pfizer outside the submitted work. J. Casalegno reported 'other' from Pfizer and grants from Sanofi outside the submitted work. M. Rosa-Calatrava reported a patent to WO2016/146836 licensed (Signia Therapeutics), a patent to WO2017/174593 licensed (Signia Therapeutics), and a patent to WO2019/224489 licensed (Signia Therapeutics), and is the co-founder of Signia Therapeutics SAS. S. Trouillet-Assant reported non-financial support from BioMérieux outside the submitted work. A. Garcia-Sastre reported 'other' from Vivaldi Biosciences, Pagoda, Contrafect, Vaxalto, Accurius, Curelab oncology, and Curelab veterinary, personal fees from Avimex, 7Hills, Esperovax, Pfizer, Farmak, Applied Biological Laboratories, Paratus, Pharmamar, Pfizer, and Synairgen, grants from Pfizer, Pharmamar, Blade Therapeutics, Avimex, Accurius, Dyna-vax, Kenall Manufacturing, ImmunityBio, Nanocomposix, Merck, Model Medicines, Atea Pharma, Shenwa Biosciences, Johnson & Johnson, 7 Hills, Hexamer, N-fold LLC, and Applied Biological Laboratories outside the submitted work, in addition, A. Garcia-Sastre had a patent for influenza virus vaccines and uses thereof issued, and invited speaker in meeting events organized by Seqirus, Janssen, Abbott, and Astrazeneca. J. Casanova reported a patent to PCT/US2021/ 042741 pending. No other disclosures were reported., We thank Dr. Cato Jacobs for her contribution to the sampling of UZLeuven patients in Belgium. The Laboratory of Human Genetics of Infectious Diseases is supported by the Howard Hughes Medical Institute, the Rockefeller University, the St. Giles Foundation, the National Institutes of Health (NIH, R01AI088364 and R01AI163029), the National Center for Advancing Translational Sciences, NIH Clinical and Translational Science Award program (UL1 TR001866), the Fisher Center for Alzheimer’s Research Foundation, the Meyer Foundation, the JPB Foundation, the French National Research Agency (ANR) under the 'Investments for the Future' program (ANR-10-IAHU-01), the Integrative Biology of Emerging Infectious Diseases Laboratory of Excellence (ANR-10-LABX-62-IBEID), the French Foundation for Medical Research (EQU201903007798), the ANRS-COV05, ANR-RHU program ANR-21-RHUS-08, ANR GENVIR (ANR-20-CE93-003), ANR GenMISC (ANR-21-COVR-0039), and ANR AABIFNCOV (ANR-20-CO11-0001) projects, the European Union’s Horizon 2020 research and innovation program under grant agreement 824110 (EASI-genomics), the HORIZON-HLTH-2021-DISEASE-04 program under grant agreement 01057100 (UNDINE), the Square Foundation, Grandir–Fonds de solidarité pour l’enfance, the Fondation du Souffle, the SCOR Corporate Foundation for Sci-ence, the French Ministry of Higher Education, Research, and Innovation (MESRI-COVID-19), Institut National de la Santé et de la Recherche Médicale (INSERM), REACTing-INSERM, and the Université Paris Cité. This work was partly supported by the Center for Research on Influenza Pathogenesis and Transmis-sion, a National Institute of Allergy and Infectious Diseases (NIAID)–funded Center of Excellence for Influenza Research and Response (contract no. 75N93021C00014), and the FLUOMICS Consortium (NIH-NIAID grant U19AI135972) to both A. García-Sastre and R.A. Medina, and by NIAID grant U19AI142733 and U19AI168631 to A. García-Sastre. Work in the Medina laboratory was also supported by the PIA ACT 1408, FONDECYT 1161971 and 1212023 grants from Agencia Nacional de Investigación y De-sarrollo of Chile. The VirPath team is supported by INSERM REACTing (Research & Action Emerging Infectious Diseases), CNRS, and Mérieux Research grants. B. Padey is supported by an ANRT CIFRE PhD scholarship. For the Lyon cohort, specimen collection and study was supported by a grant from the French Ministry of Health PHRC-I 2013 ANTIGRIPPE. C. Rodríguez-Gallego and colleagues were supported by the Instituto de Salud Carlos III (COV20_01333, COV20_01334, and PI12/01565, Spanish Ministry for Science and Innovation RTC-2017-6471-1, AEI/ FEDER, UE), Grupo DISA, Fundación MAPFRE Guanarteme, Sociedad Española de Neumología y Cirugía Torácica and Cab-ildo Insular de Tenerife (CGIEU0000219140 and 'Apuestas, científicas del Instituto Tecnológico y de Energías Renovables para colaborar en la lucha contra la COVID-19'). E. Andreakos is supported by the Hellenic Foundation for Research and Innovation (INTERFLU, no. 1574). P. Bastard was supported by the French Foundation for Medical Research (EA20170638020) and by the MD-PhD program of the Imagine Institute (with the support of the Fondation Bettencourt-Schueller). This study was supported by Plan Nacional de I+D+i 2013-2016 and In-stituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Ciencia, Innovación y Universidades, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0009), cofinanced by European Regional Development Fund 'A way to achieve Eu-rope', Operative Program Intelligence Growth 2014-2020 (CB21/13/00006) also was supported by CIBER-Consorcio Centro de Investigación Biomédica en Red, Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación and Unión Europea–Next Generation EU and Consejería de Economía, Conocimiento, Empresas y Universidad, Secretaría General de Universidades, Investigación y Tecnología, Junta de Andalucía, Spain (P18-RT-3320). I. Meyts is a Senior Clinical Investigator at the Research Foundation–Flanders and is supported by the CSL Behring Chair of Primary Immunodeficiencies, a CSL-Behring Research Grant, KU Leuven C1 grant C16/18/007, a VIB GC PID Grant, Fonds Wetenschappelijk Onderzoek grants G0C8517N, G0B5120N, and G0E8420N, and the Jeffrey Modell Foundation. Open Access funding provided by Rockefeller University. Author contributions: Q. Zhang, A. Pizzorno, L. Miorin, P., The Laboratory of Human Genetics of Infectious Diseases is supported by the Howard Hughes Medical Institute, the Rockefeller University, the St. Giles Foundation, the National Institutes of Health (NIH, R01AI088364 and R01AI163029), the National Center for Advancing Translational Sciences, NIH Clinical and Translational Science Award program (UL1 TR001866), the Fisher Center for Alzheimer’s Research Foundation, the Meyer Foundation, the JPB Foundation, the French National Research Agency (ANR) under the 'Investments for the Future' program (ANR-10-IAHU-01), the Integrative Biology of Emerging Infectious Diseases Laboratory of Excellence (ANR-10-LABX-62-IBEID), the French Foundation for Medical Research (EQU201903007798), the ANRS-COV05, ANR-RHU program ANR-21-RHUS-08, ANR GENVIR (ANR-20-CE93-003), ANR GenMISC (ANR-21-COVR-0039), and ANR AABIFNCOV (ANR-20-CO11-0001) projects, the European Union’s Horizon 2020 research and innovation program under grant agreement 824110 (EASI-genomics), the HORIZON-HLTH-2021-DISEASE-04 program under grant agreement 01057100 (UNDINE), the Square Foundation, Grandir–Fonds de solidarité pour l’enfance, the Fondation du Souffle, the SCOR Corporate Foundation for Science, the French Ministry of Higher Education, Research, and Innovation (MESRI-COVID-19), Institut National de la Santé et de la Recherche Médicale (INSERM), REACTing-INSERM, and the Université Paris Cité. This work was partly supported by the Center for Research on Influenza Pathogenesis and Transmission, a National Institute of Allergy and Infectious Diseases (NIAID)–funded Center of Excellence for Influenza Research and Response (contract no. 75N93021C00014), and the FLUOMICS Consortium (NIH-NIAID grant U19AI135972) to both A. García-Sastre and R.A. Medina, and by NIAID grant U19AI142733 and U19AI168631 to A. García-Sastre. Work in the Medina laboratory was also supported by the PIA ACT 1408, FONDECYT 1161971 and 1212023 grants from Agencia Nacional de Investigación y De-sarrollo of Chile. The VirPath team is supported by INSERM REACTing (Research & Action Emerging Infectious Diseases), CNRS, and Mérieux Research grants. B. Padey is supported by an ANRT CIFRE PhD scholarship. For the Lyon cohort, specimen collection and study was supported by a grant from the French Ministry of Health PHRC-I 2013 ANTIGRIPPE. C. Rodríguez-Gallego and colleagues were supported by the Instituto de Salud Carlos III (COV20_01333, COV20_01334, and PI12/01565, Spanish Ministry for Science and Innovation RTC-2017-6471-1, AEI/ FEDER, UE), Grupo DISA, Fundación MAPFRE Guanarteme, Sociedad Española de Neumología y Cirugía Torácica and Cabildo Insular de Tenerife (CGIEU0000219140 and 'Apuestas, científicas del Instituto Tecnológico y de Energías Renovables para colaborar en la lucha contra la COVID-19'). E. Andreakos is supported by the Hellenic Foundation for Research and, Innovation (INTERFLU, no. 1574). P. Bastard was supported by the French Foundation for Medical Research (EA20170638020) and by the MD-PhD program of the Imagine Institute (with the support of the Fondation Bettencourt-Schueller). This study was supported by Plan Nacional de I+D+i 2013-2016 and In-stituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Ciencia, Innovación y Universidades, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0009), cofinanced by European Regional Development Fund 'A way to achieve Europe', Operative Program Intelligence Growth 2014-2020 (CB21/13/00006) also was supported by CIBER-Consorcio Centro de Investigación Biomédica en Red, Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación and Unión Europea–Next Generation EU and Consejería de Economía, Conocimiento, Empresas y Universidad, Secretaría General de Universidades, Investigación y Tecnología, Junta de Andalucía, Spain (P18-RT-3320). I. Meyts is a Senior Clinical Investigator at the Research Foundation–Flanders and is supported by the CSL Behring Chair of Primary Immunodeficiencies, a CSL-Behring Research Grant, KU Leuven C1 grant C16/18/007, a VIB GC PID Grant, Fonds Wetenschappelijk Onderzoek grants G0C8517N, G0B5120N, and G0E8420N, and the Jeffrey Modell Foundation. Open Access funding provided by Rockefeller University., ANR-20-CO11-0001,AABIFNCOV,Bases génétiques et immunologiques des auto-anticorps contre les interférons de type I prédisposant aux formes sévères de COVID-19.(2020), ANR-20-CE93-0003,GENVIR,Analyse multi-omique de l'immunité anti-virale: de l'identification des circuits biologiques pertinents à la découverte de défauts monogéniques héréditaires de l'immunité chez les patients avec infections virales sévères(2020), ANR-21-COVR-0039,GenMIS-C,Recherche des Déficits immunitaires innées monogéniques prédisposant au syndrome inflammatoire multisystémique chez l'enfant.(2021), and ANR-21-RHUS-0008,COVIFERON,Covid-19 and interferons: from discovery to therapy(2021)

Subjects
INTERFERON, Cerba HealthCare Group, Immunology, SEVERE COVID-19, Pneumònia, Autoanticossos, DETERMINANTS, IMMUNITY, Grip, NEUTRALIZING ANTIBODIES, 3C-Dijon Study, INFECTION, Influenza, Human, Medicine and Health Sciences, Immunology and Allergy, Humans, COVID Human Genetic Effort, MYASTHENIA-GRAVIS PATIENTS, Autoantibodies, REIPI INF Working Group, Etablissement Français du Sang Study Group, Yellow Fever Vaccine, COVID-19, Pneumonia, ALLELES, Lyon Antigrippe Working Group, Influenza, ALPHA, Settore MED/03, Interferon Type I, [SDV.IMM]Life Sciences [q-bio]/Immunology, BURDEN, Constances Cohort
Abstract

Autoantibodies neutralizing type I interferons (IFNs) can underlie critical COVID-19 pneumonia and yellow fever vaccine disease. We report here on 13 patients harboring autoantibodies neutralizing IFN-α2 alone (five patients) or with IFN-ω (eight patients) from a cohort of 279 patients (4.7%) aged 6-73 yr with critical influenza pneumonia. Nine and four patients had antibodies neutralizing high and low concentrations, respectively, of IFN-α2, and six and two patients had antibodies neutralizing high and low concentrations, respectively, of IFN-ω. The patients' autoantibodies increased influenza A virus replication in both A549 cells and reconstituted human airway epithelia. The prevalence of these antibodies was significantly higher than that in the general population for patients 70 yr of age (3.1 vs. 4.4%, P = 0.68). The risk of critical influenza was highest in patients with antibodies neutralizing high concentrations of both IFN-α2 and IFN-ω (OR = 11.7, P = 1.3 × 10-5), especially those, The Laboratory of Human Genetics of Infectious Diseases is supported by the Howard Hughes Medical Institute, the Rockefeller University, the St. Giles Foundation, the National Institutes of Health (NIH; R01AI088364 and R01AI163029), the National Center for Advancing Translational Sciences, NIH Clinical and Translational Science Award program (UL1 TR001866), the Fisher Center for Alzheimer’s Research Foundation, the Meyer Foundation, the JPB Foundation, the French National Research Agency (ANR) under the “Investments for the Future” program (ANR-10-IAHU-01), the Integrative Biology of Emerging Infectious Diseases Laboratory of Excellence (ANR-10-LABX-62-IBEID), the French Foundation for Medical Research (EQU201903007798), the ANRS-COV05, ANR-RHU program ANR-21-RHUS-08, ANR GENVIR (ANR-20-CE93-003), ANR GenMISC (ANR-21-COVR-0039), and ANR AABIFNCOV (ANR-20-CO11-0001) projects, the European Union’s Horizon 2020 research and innovation program under grant agreement 824110 (EASI-genomics), the HORIZON-HLTH-2021-DISEASE-04 program under grant agreement 01057100 (UNDINE), the Square Foundation, Grandir–Fonds de solidarité pour l’enfance, the Fondation du Souffle, the SCOR Corporate Foundation for Science, the French Ministry of Higher Education, Research, and Innovation (MESRI-COVID-19), Institut National de la Santé et de la Recherche Médicale (INSERM), REACTing-INSERM, and the Université Paris Cité. This work was partly supported by the Center for Research on Influenza Pathogenesis and Transmission, a National Institute of Allergy and Infectious Diseases (NIAID)–funded Center of Excellence for Influenza Research and Response (contract no. 75N93021C00014), and the FLUOMICS Consortium (NIH-NIAID grant U19AI135972) to both A. García-Sastre and R.A. Medina, and by NIAID grant U19AI142733 and U19AI168631 to A. García-Sastre. Work in the Medina laboratory was also supported by the PIA ACT 1408, FONDECYT 1161971 and 1212023 grants from Agencia Nacional de Investigación y Desarrollo of Chile. The VirPath team is supported by INSERM REACTing (Research & Action Emerging Infectious Diseases), CNRS, and Mérieux Research grants. B. Padey is supported by an ANRT CIFRE PhD scholarship. For the Lyon cohort, specimen collection and study was supported by a grant from the French Ministry of Health PHRC-I 2013 ANTIGRIPPE. C. Rodríguez-Gallego and colleagues were supported by the Instituto de Salud Carlos III (COV20_01333, COV20_01334, and PI12/01565, Spanish Ministry for Science and Innovation RTC-2017-6471-1; AEI/FEDER, UE), Grupo DISA, Fundación MAPFRE Guanarteme, Sociedad Española de Neumología y Cirugía Torácica and Cabildo Insular de Tenerife (CGIEU0000219140 and “Apuestas, científicas del Instituto Tecnológico y de Energías Renovables para colaborar en la lucha contra la COVID-19”). E. Andreakos is supported by the Hellenic Foundation for Research and Innovation (INTERFLU, no. 1574). P. Bastard was supported by the French Foundation for Medical Research (EA20170638020) and by the MD-PhD program of the Imagine Institute (with the support of the Fondation Bettencourt-Schueller). This study was supported by Plan Nacional de I+D+i 2013-2016 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Ciencia, Innovación y Universidades, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0009); cofinanced by European Regional Development Fund “A way to achieve Europe”; Operative Program Intelligence Growth 2014-2020 (CB21/13/00006) also was supported by CIBER-Consorcio Centro de Investigación Biomédica en Red, Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación and Unión Europea–Next Generation EU and Consejería de Economía, Conocimiento, Empresas y Universidad, Secretaría General de Universidades, Investigación y Tecnología, Junta de Andalucía, Spain (P18-RT-3320). I. Meyts is a Senior Clinical Investigator at the Research Foundation–Flanders and is supported by the CSL Behring Chair of Primary Immunodeficiencies, a CSL-Behring Research Grant, KU Leuven C1 grant C16/18/007, a VIB GC PID Grant, Fonds Wetenschappelijk Onderzoek grants G0C8517N, G0B5120N, and G0E8420N, and the Jeffrey Modell Foundation. Open Access funding provided by Rockefeller University.

Published
2022
Full Text
View/download PDF

35. ESCMID COVID-19 guidelines: diagnostic testing for SARS-CoV-2

Author

Can, Füsun (ORCID 0000-0001-9387-2526 & YÖK ID 103165), Fragkou, Paraskevi C.; De Angelis, Giulia; Menchinelli, Giulia; Garcia, Federico; Morfin-Sherpa, Florence; Dimopoulou, Dimitra; Mack, Elisabeth; de Salazar, Adolfo; Grossi, Adriano; Lytras, Theodore; Skevaki, Chrysanthi, Koç Üniversitesi İş Bankası Enfeksiyon Hastalıkları Uygulama ve Araştırma Merkezi (EHAM) / Koç University İşbank Center for Infectious Diseases (KU-IS CID), School of Medicine, Can, Füsun (ORCID 0000-0001-9387-2526 & YÖK ID 103165), Fragkou, Paraskevi C.; De Angelis, Giulia; Menchinelli, Giulia; Garcia, Federico; Morfin-Sherpa, Florence; Dimopoulou, Dimitra; Mack, Elisabeth; de Salazar, Adolfo; Grossi, Adriano; Lytras, Theodore; Skevaki, Chrysanthi, Koç Üniversitesi İş Bankası Enfeksiyon Hastalıkları Uygulama ve Araştırma Merkezi (EHAM) / Koç University İşbank Center for Infectious Diseases (KU-IS CID), and School of Medicine

Abstract

Scope: the objective of these guidelines is to identify the most appropriate diagnostic test and/or diagnostic approach for SARS-CoV-2. The recommendations are intended to provide guidance to clinicians, clinical microbiologists, other health care personnel, and decision makers. Methods: an ESCMID COVID-19 guidelines task force was established by the ESCMID Executive Committee. A small group was established, half appointed by the chair and the remaining selected with an open call. Each panel met virtually once a week. For all decisions, a simple majority vote was used. A list of clinical questions using the PICO (population, intervention, comparison, outcome) format was developed at the beginning of the process. For each PICO, two panel members performed a literature search focusing on systematic reviews, with a third panellist involved in case of inconsistent results. Quality of evidence assessment was based on the GRADE-ADOLOPMENT (Grading of Recommendations Assessment, Development and Evaluation - adoption, adaptation, and de novo development of recommendations) approach. Recommendations: a total of 43 PICO questions were selected that involve the following types of populations: (a) patients with signs and symptoms of COVID-19; (b) travellers, healthcare workers, and other individuals at risk for exposure to SARS-CoV-2; (c) asymptomatic individuals, and (d) close contacts of patients infected with SARS-CoV-2. The type of diagnostic test (commercial rapid nucleic acid amplification tests and rapid antigen detection), biomaterial, time since onset of symptoms/contact with an infectious case, age, disease severity, and risk of developing severe disease are also taken into consideration., "Hycor Biomedical; Bencard Allergie; Thermo Fisher Scientific; Mead Johnson Nutrition; Universities Giessen and Marburg Lung Center; German Center for Lung Research; University Hospital Giessen and Marburg; Deutsche Forschungsgemeinschaft-funded SFB 1021; KFO 309 (P10); SK 317/1-1; Foundation for Pathobiochemistry and Molecular Diagnostics; Fundacion Progreso y Salud; Consejería de Salud; Junta de Andalucía; Philipps University Marburg Fundation of the Faculty of Medicine; Deutsche Jose Carreras Leukamie-Stiftung"

Published
2022

36. Intensity and Dynamics of Anti-SARS-CoV-2 Immune Responses after BNT162b2 mRNA Vaccination: Implications for Public Health Vaccination Strategies

Author

Speletas, Matthaios, primary, Voulgaridi, Ioanna, additional, Sarrou, Styliani, additional, Dadouli, Aikaterini, additional, Mouchtouri, Varvara A., additional, Nikoulis, Dimitrios J., additional, Tsakona, Maria, additional, Kyritsi, Maria A., additional, Peristeri, Athanasia-Marina, additional, Avakian, Ioanna, additional, Nasika, Asimina, additional, Fragkou, Paraskevi C., additional, Moschopoulos, Charalampos D., additional, Zoubouneli, Stamatia, additional, Onoufriadis, Ilias, additional, Anagnostopoulos, Lemonia, additional, Matziri, Alexia, additional, Papadamou, Georgia, additional, Theodoridou, Aikaterini, additional, Tsiodras, Sotirios, additional, and Hadjichristodoulou, Christos, additional

Published
2022
Full Text
View/download PDF

37. sj-docx-1-tan-10.1177_17562864221099472 – Supplemental material for Effects of low molecular weight heparin and fondaparinux on mortality, hemorrhagic and thrombotic complications in COVID-19 patients

Author

Fragkou, Paraskevi C., Palaiodimou, Lina, Stefanou, Maria Ioanna, Katsanos, Aristeidis H., Lambadiari, Vaia, Paraskevis, Dimitrios, Andreadou, Elisabeth, Dimopoulou, Dimitra, Zompola, Christina, Ferentinos, Panagiotis, Vassilakopoulos, Theodoros I., Kotanidou, Anastasia, Sfikakis, Petros P., Tsiodras, Sotirios, and Tsivgoulis, Georgios

Subjects
FOS: Clinical medicine, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, 110904 Neurology and Neuromuscular Diseases
Abstract

Supplemental material, sj-docx-1-tan-10.1177_17562864221099472 for Effects of low molecular weight heparin and fondaparinux on mortality, hemorrhagic and thrombotic complications in COVID-19 patients by Paraskevi C. Fragkou, Lina Palaiodimou, Maria Ioanna Stefanou, Aristeidis H. Katsanos, Vaia Lambadiari, Dimitrios Paraskevis, Elisabeth Andreadou, Dimitra Dimopoulou, Christina Zompola, Panagiotis Ferentinos, Theodoros I. Vassilakopoulos, Anastasia Kotanidou, Petros P. Sfikakis, Sotirios Tsiodras and Georgios Tsivgoulis in Therapeutic Advances in Neurological Disorders

Published
2022
Full Text
View/download PDF

38. ESCMID COVID-19 guidelines: diagnostic testing for SARS-CoV-2

Author

Fragkou, Paraskevi C. De Angelis, Giulia Menchinelli, Giulia Can, Fusun Garcia, Federico Morfin-Sherpa, Florence Dimopoulou, Dimitra Mack, Elisabeth de Salazar, Adolfo Grossi, Adriano Lytras, Theodore Skevaki, Chrysanthi

Abstract

SCOPE: The objective of these guidelines is to identify the most appropriate diagnostic test and/or diagnostic approach for SARS-CoV-2. The recommendations are intended to provide guidance to clinicians, clinical microbiologists, other health care personnel, and decision makers. METHODS: An ESCMID COVID-19 guidelines task force was established by the ESCMID Executive Committee. A small group was established, half appointed by the chair, and the remaining selected with an open call. Each panel met virtually once a week. For all decisions, a simple majority vote was used. A list of clinical questions using the PICO (population, intervention, comparison, outcome) format was developed at the beginning of the process. For each PICO, two panel members performed a literature search focusing on systematic reviews with a third panelist involved in case of inconsistent results. Quality of evidence assessment was based on the GRADE-ADOLOPMENT approach. QUESTIONS ADDRESSED BY THE GUIDELINE AND RECOMMENDATIONS: A total of 43 PICO questions were selected that involve the following types of populations: 1) patients with signs and symptoms of COVID-19; 2) travelers, healthcare workers, and other individuals at risk for exposure to SARS-CoV-2; 3) asymptomatic individuals and 4) close contacts of patients infected with SARS-CoV-2. The type of diagnostic test (commercial rapid nucleic acid amplification tests, and rapid antigen detection), biomaterial, time since onset of symptoms/contact with an infectious case, age, disease severity, and risk of developing severe disease are also taken into consideration.

Published
2022

39. Ptsd, Depersonalization and Psychosomatic Symptoms in Health Care Workers During the Covid-19 Outbreak

Author

Kontoangelos, Konstantinos, primary, Poulakou, Garyfallia, additional, Economou, Marina, additional, Leontis, Konstantinos, additional, Fragkou, Paraskevi C, additional, Baraboutis, Ioannis, additional, Rapti, Vasiliki, additional, Tsagalou, Eleftheria, additional, Koufatzidis, Konstantinos, additional, Sympardi, Styliani, additional, Argyraki, Katerina, additional, Panagopoulos, Periklis, additional, Latsios, George, additional, Papageorgiou, Christos, additional, Tsiori, Sofia, additional, Tsiodras, Sotirios, additional, Dimopoulos, Meletios A, additional, Syrigos, Konstantinos, additional, and Papageorgiou, Charalabos, additional

Published
2022
Full Text
View/download PDF

40. Effects of low molecular weight heparin and fondaparinux on mortality, hemorrhagic and thrombotic complications in COVID-19 patients

Author

Fragkou, Paraskevi C., primary, Palaiodimou, Lina, additional, Stefanou, Maria Ioanna, additional, Katsanos, Aristeidis H., additional, Lambadiari, Vaia, additional, Paraskevis, Dimitrios, additional, Andreadou, Elisabeth, additional, Dimopoulou, Dimitra, additional, Zompola, Christina, additional, Ferentinos, Panagiotis, additional, Vassilakopoulos, Theodoros I., additional, Kotanidou, Anastasia, additional, Sfikakis, Petros P., additional, Tsiodras, Sotirios, additional, and Tsivgoulis, Georgios, additional

Published
2022
Full Text
View/download PDF

41. Transmission of Infections during Cardiopulmonary Resuscitation

Author

Fragkou, Paraskevi C., primary, Dimopoulou, Dimitra, additional, Latsios, George, additional, Koudounis, Panagiotis, additional, Synetos, Andreas, additional, Dimopoulou, Anastasia, additional, Tsioufis, Konstantinos, additional, Papaevangelou, Vassiliki, additional, and Tsiodras, Sotirios, additional

Published
2021
Full Text
View/download PDF

42. Angiotensin‐converting‐enzyme insertion/deletion polymorphism, ACE activity, and COVID‐19: A rather controversial hypothesis. A case‐control study

Author

Papadopoulou, Anna, primary, Fragkou, Paraskevi C., additional, Maratou, Eirini, additional, Dimopoulou, Dimitra, additional, Kominakis, Antonis, additional, Kokkinopoulou, Ioanna, additional, Kroupis, Christos, additional, Nikolaidou, Athina, additional, Antonakos, Georgios, additional, Papaevangelou, Vasiliki, additional, Armaganidis, Apostolos, additional, Tsantes, Argirios, additional, Polyzogopoulou, Eftychia, additional, Tsiodras, Sotirios, additional, Antoniadou, Anastasia, additional, and Moutsatsou, Paraskevi, additional

Published
2021
Full Text
View/download PDF

43. Respiratory viral co‐infections in patients with COVID‐19 and associated outcomes: A systematic review and meta‐analysis.

Author

Krumbein, Hanna, Kümmel, Lara S., Fragkou, Paraskevi C., Thölken, Clemens, Hünerbein, Ben L., Reiter, Rieke, Papathanasiou, Konstantinos A., Renz, Harald, and Skevaki, Chrysanthi

Abstract

The aim of this systematic review and meta‐analysis was to critically assess the published literature related to community‐acquired viral co‐infections and COVID‐19 and to evaluate the prevalence, most identified co‐pathogens, and relevant risk factors. Furthermore, we aimed to examine the clinical features and outcomes of co‐infected compared to mono‐infected COVID‐19 patients. We systematically searched PubMed, Web of Science, Embase, Scopus, and The Cochrane Library for studies published from 1 November 2019 to 13 August 2021. We included patients of all ages and any COVID‐19 severity who were screened for respiratory viral co‐infection within 48 h of COVID‐19 diagnosis. The main outcome was the proportion of patients with a respiratory viral co‐infection. The systematic review was registered to PROSPERO (CRD42021272235). Out of 6053 initially retrieved studies, 59 studies with a total of 16,643 SARS‐CoV‐2 positive patients were included. The global pooled prevalence was 5.01% (95% CI 3.34%–7.27%; I2 = 95%) based on a random‐effects model, with Influenza Viruses (1.54%) and Enteroviruses (1.32%) being the most prevalent pathogens. Subgroup analyses showed that co‐infection was significantly higher in paediatric (9.39%) than adult (3.51%) patients (p‐value = 0.02). Furthermore, co‐infected patients were more likely to be dyspnoeic and the odds of fatality (OR = 1.66) were increased. Although a relatively low proportion of COVID‐19 patients have a respiratory viral co‐infection, our findings show that multiplex viral panel testing may be advisable in patients with compatible symptoms. Indeed, respiratory virus co‐infections may be associated with adverse clinical outcomes and therefore have therapeutic and prognostic implications. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

44. Serious complications of COVID-19 vaccines: A mini-review

Author

Fragkou, Paraskevi C. Dimopoulou, Dimitra

Abstract

Τhe most promising approach of fighting COVID-19 and restraining the course of this pandemic is indisputably the universal vaccination of the population with safe and effective vaccines. However, besides the common and usually mild side effects of the authorized vaccines, some rare, major adverse reactions are increasingly being reported worldwide during the post marketing surveillance phase of vaccines' circulation, such as anaphylaxis, vaccine-induced thrombotic thrombocytopenia, myopericarditis and Guillain-Barré syndrome. Despite rare cases with complications from COVID-19 vaccines, the net benefit-risk ratio shows a clearly favorable balance towards COVID-19 vaccination for all age and sex groups. Vaccine adverse events should be identified early and monitored closely. As many aspects of these adverse effects remain still obscure for the medical community and the relevant stakeholders, it is also highly important to be promptly reported. Nonetheless, these complications should not constitute a reason to change the vaccine policy and further studies are needed to alleviate concerns and reluctance to COVID-19 vaccinations.

Published
2021

45. Rare Presentation of a Metastatic Pancreatic Neuroendocrine Neoplasm Presenting with Atrial Flutter

Author

Fragkou, Paraskevi C. Papadopoulos, Ioannis A. Papadopoulos, Antonios Kontoveros, Evangelos-Achilleas Kaltsas, Gregory Vassilara, Foula

Subjects
cardiovascular system, cardiovascular diseases
Abstract

Pancreatic neuroendocrine neoplasms (PanNENs) rarely secrete serotonin, which is the main cause of carcinoid syndrome. One of its unusual manifestations is carcinoid heart disease or Hedinger's syndrome which is seldom accompanied by cardiac arrhythmias. We report the case of an 88-year-old woman who presented with recently experienced episodes of palpitations and a newly developed atrial flutter with a ventricular rate of 130 beats per minute. Echocardiography revealed thickened and tethered tricuspid and pulmonary valve leaflets causing severe valvular regurgitation and right ventricular dilatation. Episodes of intermittent diarrhoea over the previous 2 years were mentioned, making carcinoid syndrome our working diagnosis. The 5-hydroxyindoleacetic acid (5-HIAA) levels in a 24-hour urine collection specimen were elevated. Conventional imaging studies and a Ga-68 dodecane tetraacetic acid tyrosine-3-octreotate (DOTATATE) positron emission tomography/computer tomography (PET/CT) scan revealed the presence of a metastatic PanNEN arising from the pancreatic tail. The patient was managed with lanreotide and telotristat with remarkable improvement of her symptoms. To our knowledge, this is the first reported case of carcinoid syndrome presenting with atrial flutter as the initial symptom. LEARNING POINTS: Ultrasonography findings can indicate or lead to the diagnosis of carcinoid heart disease or Hedinger's syndrome.Clinicians should investigate rarer causes of atrial flutter when common ones are excluded.Even in advanced metastatic disease, complete remission of symptoms may be achieved with somatostatin analogues along with telotristat ethyl.

Published
2021

47. How to interpret and use COVID-19 serology and immunology tests

Author

Ong, David S. Y. Fragkou, Paraskevi C. Schweitzer, Valentijn A. and Chemaly, Roy F. Moschopoulos, Charalampos D. Skevaki, Chrysanthi ESCMID Study Grp Respiratory Viruses ESGR

Abstract

Background: Although molecular tests are considered the reference standard for coronavirus disease 2019 (COVID-19) diagnostics, serological and immunological tests may be useful in specific settings. Objectives: This review summarizes the underlying principles and performance of COVID-19 serological and immunological testing. Sources: Selected peer-reviewed publications on COVID-19 related serology and immunology published between December 2019 and March 2021. Content: Serological tests are highly specific but heterogeneous in their sensitivity for the diagnosis of COVID-19. For certain indications, including delayed disease presentations, serological tests can have added value. The presence of antibodies against SARS-CoV-2 may indicate a recent or past COVID-19 infection. Lateral flow immunoassay (LFIA) antibody tests have the advantages of being easy and fast to perform, but many have a low sensitivity in acute settings. Enzyme-linked immunosorbent assay (ELISA) and chemiluminescence immunoassays (CLIAs) have higher sensitivities. Besides humoral immunity, cellular immunity is also essential for successful host defences against viruses. Enzyme-linked immunospot (ELISpot) assays can be used to measure T-cell responses against SARS-CoV-2. The presence of cross-reactive SARS-CoV-2-specific T cells in never exposed patients suggests the possibility of cellular immunity induced by other circulating coronaviruses. T-cell responses against SARS-CoV-2 have also been detected in recovered COVID-19 patients with no detectable antibodies. Implications: Serological and immunological tests are primarily applied for population-based seroprevalence studies to evaluate the effectiveness of COVID-19 control measures and increase our understanding of the immunology behind COVID-19. Combining molecular diagnostics with serological tests may optimize the detection of COVID-19. As not all infected patients will develop antibodies against SARS-CoV-2, assessment of cellular immunity may provide complementary information on whether a patient has been previously infected with COVID-19. More studies are needed to understand the correlations of these serological and immunological parameters with protective immunity, taking into account the different circulating virus variants. David S.Y. Ong, Clin Microbiol Infect 2021;27:981 (c) 2021 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Published
2021

48. A case of encapsulating peritoneal sclerosis in a patient with chronic schistosomiasis

Author

Fragkou, Paraskevi C. Karofylakis, Emmanouil Oikonomopoulos, Nikolaos Piperaki, Evangelia T. Tsiodras, Sotirios Kavvatha, Dimitra

Abstract

Encapsulating peritoneal sclerosis (EPS) is a debilitating condition, mainly associated with long-term peritoneal dialysis, where up-regulation of intra-abdominal inflammatory pathways leads to a fibrocollagenous peritoneal membrane formation resembling a cocoon. EPS causes intestinal encapsulation leading to bowel obstruction and dilatation. Chronic schistosomiasis is characterized by dysregulation of pro-inflammatory and anti-inflammatory cytokines. EPS has never been reported before in patients with chronic schistosomiasis. We report the first, to our knowledge, case of a 57-year-old male originated from Burkina Faso with chronic intestinal and urogenital schistosomiasis and EPS. Although causality cannot be established solely by this case, we hypothesize that EPS may be the result of chronic inflammatory activation, due to immune dysregulation driven by chronic schistosomiasis. The potential pathogenetic linkage between these two conditions should be further explored. (C) 2021 The Author(s). Published by Elsevier Ltd.

Published
2021

49. Update in Viral Infections in the Intensive Care Unit

Author

Fragkou, Paraskevi C. Moschopoulos, Charalampos D. Karofylakis, Emmanouil Kelesidis, Theodoros Tsiodras, Sotirios

Abstract

The advent of highly sensitive molecular diagnostic techniques has improved our ability to detect viral pathogens leading to severe and often fatal infections that require admission to the Intensive Care Unit (ICU). Viral infections in the ICU have pleomorphic clinical presentations including pneumonia, acute respiratory distress syndrome, respiratory failure, central or peripheral nervous system manifestations, and viral-induced shock. Besides de novo infections, certain viruses fall into latency and can be reactivated in both immunosuppressed and immunocompetent critically ill patients. Depending on the viral strain, transmission occurs either directly through contact with infectious materials and large droplets, or indirectly through suspended air particles (airborne transmission of droplet nuclei). Many viruses can efficiently spread within hospital environment leading to in-hospital outbreaks, sometimes with high rates of mortality and morbidity, thus infection control measures are of paramount importance. Despite the advances in detecting viral pathogens, limited progress has been made in antiviral treatments, contributing to unexpectedly high rates of unfavorable outcomes. Herein, we review the most updated data on epidemiology, common clinical features, diagnosis, pathogenesis, treatment and prevention of severe community- and hospital-acquired viral infections in the ICU settings.

Published
2021

50. SARS-CoV-2 Antigenemia as a Confounding Factor in Immunodiagnostic Assays: A Case Study

Author

Belogiannis, Konstantinos, primary, Florou, Venetia A., additional, Fragkou, Paraskevi C., additional, Ferous, Stefanos, additional, Chatzis, Loukas, additional, Polyzou, Aikaterini, additional, Lagopati, Nefeli, additional, Vassilakos, Demetrios, additional, Kittas, Christos, additional, Tzioufas, Athanasios G., additional, Tsiodras, Sotirios, additional, Sourvinos, George, additional, and Gorgoulis, Vassilis G., additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results